Artelo Biosciences (ARTL) Q1 2026 earnings summary

Executive summary

• Focused on developing therapeutics targeting lipid-signaling pathways, with a pipeline including ART27.13 (cancer anorexia, Phase 1b/2a), ART26.12 (FABP5 inhibitor, Phase 1), and ART12.11 (CBD cocrystal, preclinical), with ART26.12 progressing to a multiple ascending dose Phase 1 study and ART12.11 receiving favorable UK regulatory guidance and patent protection through 2038.

• ART27.13 interim Phase 2 data showed >6% mean weight gain in cancer anorexia patients versus 5% loss in placebo, with a favorable safety profile and ongoing strategic development.

• ART26.12 completed Phase 1 SAD study with favorable safety and pharmacokinetics; enrollment for multiple ascending dose Phase 1 expected in Q4 2026.

• ART12.11 exhibited improved pharmacokinetics and efficacy in nonclinical studies, with Phase 1 trials planned for H1 2026.

• Strengthened balance sheet through recent capital raise and third-party grants, supporting clinical advancement.

Financial highlights

• Net loss for Q1 2026 was $3.0 million ($4.00 per share), up from $2.4 million in Q1 2025.

• Operating expenses rose to $2.69 million from $2.38 million year-over-year, with R&D expenses decreasing to $0.8 million and G&A expenses increasing to $1.9 million.

• Cash and cash equivalents totaled $10.3 million as of March 31, 2026, up from $0.6 million at year-end 2025, primarily due to financing activities.

• Weighted average shares outstanding for Q1 2026: 739,000.

Outlook and guidance

• Expects continued R&D and G&A expenses, with future spending dependent on funding and clinical development progress; multiple clinical catalysts expected through 2027, including ART26.12 and ART12.11 Phase 1 studies.

• Substantial doubt exists about ability to continue as a going concern within one year without additional funding.

• Plans to seek further capital through equity, debt, or licensing; ongoing partnering discussions and strategic collaborations anticipated.